SecBot SecBot
DEFA14A ·Filed Nov 5, 2026

NRXP

NRX Pharmaceuticals, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed11d 10h ago SEC0001437749-26-035308
Proxy solicitation materials
Actionable Insight • Neutral

Monitor for additional proxy solicitation materials or a dissident filing (DFAN14A) that may detail the opposing candidate or proposals. The contested election introduces governance uncertainty but no immediate financial impact.

DirectionNeutral
Confidencemedium
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$2.38
T+0 close · Nov 5, 2026 · via day close
Latest settled
−7.98%
T+5 · $2.19
Vs SPY
−10.58%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $2.38entry
  2. T+1 · 8d ago 0.00%α −2.37% · $2.38
  3. T+5 · 4d ago −7.98%α −10.58% · $2.19
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NRX Pharmaceuticals filed additional definitive proxy soliciting materials (DEFA14A) on the same day as its definitive proxy statement (DEF 14A), indicating a contested director election for the 2026 annual meeting. The filing itself contains only the form header and no substantive soliciting content, but the cross-filing context confirms the election of Dennis McBride as the sole Class II director is being contested, adding governance uncertainty.

Key Financial Metrics

Vote
director election
Seats Contested
1

Key Facts

  • Filed DEFA14A on 2026-11-05, same day as DEF 14A
  • DEF 14A seeks to elect Dennis McBride as sole Class II director
  • Cross-filing context indicates a contested election
  • Market cap is $97M with normal daily move of 4.8%

Financial Impact

No financial figures stated in the filing

Risk Factors

  • Contested election may lead to increased proxy solicitation costs
  • Potential for board instability if dissident slate gains traction

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001437749-26-035308
Document: 0001437749-26-035308-index-headers.html0001437749-26-035308
Document: 0001437749-26-035308-index.html0001437749-26-035308
Document: 0001437749-26-035308.txt0001437749-26-035308

Track record

22 reports on NRXP

Performance horizon

8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 10 of 13 went positive at some point.

Filters
  1. Nov 5, 202611d ago DEFA14A Neutral 3/10 Viewing Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  2. Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  3. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
  4. Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
  5. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
  6. Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
  7. Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
  8. Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
  9. Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
  10. Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
Showing 10 of 22

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026